Johnson & Johnson forecast $2.5 billion in 2021 gross sales of its COVID-19 vaccine. (File)
London:
Johnson & Johnson on Wednesday forecast simply $2.5 billion in 2021 gross sales of its COVID-19 vaccine, which has fallen method behind rival pictures from Pfizer and Moderna as the corporate offers with vaccine manufacturing points and security considerations.
J&J mentioned it expects full-year gross sales of $91.3 billion-$92.1 billion this yr from the remainder of the enterprise, and $93.8 billion to $94.6 billion together with contribution from the single-dose vaccine.
The J&J shot, as soon as touted as an vital device for vaccinations in hard-to-reach areas, is much behind on its schedule for deliveries within the United States and Europe.
Use of the vaccine has additionally been linked to a really uncommon, probably life-threatening blood-clotting situation. Last week, US regulators added a warning to the vaccine associated to a uncommon autoimmune dysfunction.
Pfizer Inc has forecast $26 billion in gross sales of its vaccine, whereas Moderna Inc has forecast $19.2 billion in vaccine gross sales this yr. Both have been accepted within the United States final yr, whereas the J&J shot was accepted this yr.
Both firms have mentioned they anticipate to revenue from their vaccines, whereas Johnson & Johnson has mentioned it is going to make the vaccine accessible on a not-for-profit foundation throughout the pandemic.
(This story has not been edited by NDTV workers and is auto-generated from a syndicated feed.)
